摘要
目的比较桂林市荧光原位杂交法(FISH)和免疫组织化学法(IHC)检测乳腺癌组织中人表皮生长因子受体(HER-2)基因扩增及其蛋白表达情况的一致性,探讨FISH与IHC检测乳腺癌HER-2基因状态的临床意义。方法应用IHC和FISH对50例乳腺癌患者HER-2蛋白表达、基因扩增情况及17号染色体倍体性进行检测,分析IHC与FISH检测HER-2基因状态的差异以及HER-2蛋白状态与17号染色体倍体性的相关性。结果FISH与IHC结果总的符合率为82.0%,两者之间存在较好的一致性(kappa=0.640),FISH检测IHC结果为3+、2+和0/1+者的符合率分别为92.9%、70.0%和80.8%;IHC3+及2+者出现17号染色体多体性的几率比IHC0/1+者高(P<0.05)。结论FISH可以准确和稳定地检测乳腺癌组织中HER-2的基因状态及17号染色体倍体性;FISH检测IHC3+者符合率较高,FISH与IHC的差异主要在于IHC2+和IHC0/+组,IHC仅作为检测HER-2基因状态的初筛方法,而IHC结果为2+或0/1+者的HER-2基因状态必须应用FISH进一步确定。
Obsjective To research the concordance between immunohistochemistry （IHC） and fluorescence in situ hybridization （FISH） assessment for HER-2 status in breast cancer patients. Methods Detecting the HER-2 gene amplification and polysomy 17 by FISH and HER-2 protein status by IHC in 50 cases of breast cancers, analyzed the concordance of these two tools and the relationship between polysomy 17 and HER-2 protein status. Results The concordance of FISH in the cases of IHC3＋, 2＋, 0/＋ were 92.9%, 70.0% and 80.8% respectively. The total concordance of the two tools in 50 cases was 82.0% （kappa=0.640）. The polysomy 17 was strongly associated with HER-2 protein （P〈0.05）. Conclusions FISH is a valuable tool with high accuracy and stability for the test of HER-2 gene amplification. The concordance between FISH and IHC is good in IHC3＋ cases, and the discordance is mainly in IHC2＋ and IHC0/＋ cases. The IHC can be used as a preliminary screening method, FISH is necessarily used to determinate the HER-2 gene status in breast cancer patients with IHC 2＋ and 0/＋.
出处
《实验与检验医学》
CAS
2010年第1期16-18,46,共4页
Experimental and Laboratory Medicine
基金
卫生部医药卫生科技发展研究中心科研基金资助(基金编号:WKJ2007-3-001)
